Profile data is unavailable for this security.
About the company
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.
- Revenue in EUR (TTM)6.66bn
- Net income in EUR189.00m
- Incorporated1987
- Employees23.74k
- LocationGrifols SAC/ Jesus y Maria, 6BARCELONA 08022SpainESP
- Phone+34 935710000
- Fax+34 935710267
- Websitehttps://www.grifols.com/
Holder | Shares | % Held |
---|---|---|
Brandes Investment Partners LPas of 31 Jan 2024 | 13.48m | 5.16% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 8.79m | 3.36% |
Santander Asset Management SA SGIICas of 31 Dec 2023 | 8.09m | 3.09% |
Capital International Ltd.as of 30 Jun 2024 | 7.07m | 2.70% |
M&G Investment Management Ltd.as of 31 Jan 2024 | 3.09m | 1.18% |
Robeco Institutional Asset Management BVas of 30 Apr 2024 | 1.70m | 0.65% |
HSBC Global Asset Management (France) SAas of 28 Jun 2024 | 1.35m | 0.52% |
Sabadell Asset Management SA SGIIC SUas of 31 Dec 2023 | 1.17m | 0.45% |
FIL Investments Internationalas of 31 Mar 2024 | 1.12m | 0.43% |
Charles Schwab Investment Management, Inc.as of 03 Jul 2024 | 749.10k | 0.29% |